Millennium Pharmacon International Stock EBITDA
| SDPC Stock | IDR 135.00 1.00 0.75% |
Millennium Pharmacon International fundamentals help investors to digest information that contributes to Millennium Pharmacon's financial success or failures. It also enables traders to predict the movement of Millennium Stock. The fundamental analysis module provides a way to measure Millennium Pharmacon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Millennium Pharmacon stock.
Millennium |
Millennium Pharmacon International Company EBITDA Analysis
Millennium Pharmacon's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Millennium Pharmacon EBITDA | 73.6 B |
Most of Millennium Pharmacon's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Millennium Pharmacon International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Millennium Pharmacon International reported earnings before interest,tax, depreciation and amortization of 73.6 B. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The ebitda for all Indonesia stocks is significantly lower than that of the firm.
Millennium EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Millennium Pharmacon's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Millennium Pharmacon could also be used in its relative valuation, which is a method of valuing Millennium Pharmacon by comparing valuation metrics of similar companies.Millennium Pharmacon is currently under evaluation in ebitda category among its peers.
Millennium Fundamentals
| Return On Equity | 0.0938 | |||
| Return On Asset | 0.0342 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 828.27 B | |||
| Shares Outstanding | 1.27 B | |||
| Shares Owned By Insiders | 87.94 % | |||
| Shares Owned By Institutions | 3.35 % | |||
| Price To Earning | 9.31 X | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 2.99 T | |||
| Gross Profit | 237.04 B | |||
| EBITDA | 73.6 B | |||
| Net Income | 9.57 B | |||
| Cash And Equivalents | 43.62 B | |||
| Cash Per Share | 34.24 X | |||
| Total Debt | 1.8 B | |||
| Debt To Equity | 257.80 % | |||
| Current Ratio | 1.15 X | |||
| Book Value Per Share | 202.66 X | |||
| Cash Flow From Operations | (18.18 B) | |||
| Earnings Per Share | 19.19 X | |||
| Number Of Employees | 1.09 K | |||
| Beta | 0.75 | |||
| Market Capitalization | 440.8 B | |||
| Total Asset | 1.21 T | |||
| Annual Yield | 0 % | |||
| Net Asset | 1.21 T | |||
| Last Dividend Paid | 1.0 |
About Millennium Pharmacon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Millennium Pharmacon International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Millennium Pharmacon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Millennium Pharmacon International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Millennium Stock
Millennium Pharmacon financial ratios help investors to determine whether Millennium Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Millennium with respect to the benefits of owning Millennium Pharmacon security.